Table 1 (abstract P9). Adverse events in ≥5% of Patients in Any Treatment Group
Patients with Adverse Event (AE), % (n) | OnabotulinumtoxinA (n=220) | Topiramate (n=142) | Total (N=282) | Switched to OnabotulinumtoxinA (n=80) |
|---|---|---|---|---|
Any AE | 45.5 (100) | 76.8 (109) | 62.4 (176) | 41.3 (33) |
 Cognitive disorder | 0.5 (1) | 12.7 (18) | 6.4 (18) | 1.3 (1) |
 Disturbance in attention | 0 | 7.7 (11) | 3.9 (11) | 0 |
 Dizziness | 2.7 (6) | 12.7 (18) | 8.2 (23) | 1.3 (1) |
 Migraine | 2.7 (6) | 2.1 (3) | 2.5 (7) | 5.0 (4) |
 Paraesthesia | 0.5 (1) | 31.0 (44) | 16.0 (45) | 0 |
 Sinusitis | 5.5 (12) | 6.3 (9) | 5.7 (16) | 6.3 (5) |
 Nausea | 0.5 (1) | 13.4 (19) | 7.1 (20) | 0 |
 Neck pain | 4.5 (10) | 2.1 (3) | 4.3 (12) | 6.3 (5) |
 Fatigue | 0.5 (1) | 13.4 (19) | 7.1 (20) | 0 |
 Depression | 1.8 (4) | 5.6 (8) | 3.5 (10) | 2.5 (2) |
 Vision blurred | 2.7 (6) | 7.0 (10) | 5.0 (14) | 3.8 (3) |
 Decreased appetite | 0 | 10.6 (15) | 5.3 (15) | 0 |